AccueilFLNA • BMV
add
Filana Therapeutics Inc
Dernière clôture
30,76 $
Plage sur l'année
30,00 $ - 56,00 $
Capitalisation boursière
77,76 M USD
Volume moyen
13,00
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 5,70 M | -36,37 % |
Résultat net | -12,54 M | 54,56 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | — | — |
EBITDA | -9,18 M | 68,57 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (USD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 95,50 M | -25,72 % |
Total des actifs | 118,36 M | -24,87 % |
Total du passif | 43,95 M | 271,56 % |
Total des capitaux propres | 74,40 M | — |
Actions en circulation | 48,31 M | — |
Ratio cours/valeur comptable | 19,97 | — |
Rentabilité des actifs | -19,25 % | — |
Retour sur capitaux | -30,62 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Résultat net | -12,54 M | 54,56 % |
Trésorerie (opérations) | -9,75 M | 84,09 % |
Trésorerie (invest.) | -501,00 k | -778,95 % |
Trésorerie (financement) | -329,00 k | -135,84 % |
Variation nette en trésorerie | -10,58 M | 82,49 % |
Flux de trésorerie dispo. | -4,32 M | 64,46 % |
À propos
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
Date de fondation
1998
Siège social
Employés
19
